Member access

4-Traders Homepage  >  Shares  >  Euronext Bruxelles  >  ABLYNX    ABLX   BE0003877942

ABLYNX

 (ABLX)

134
Delayed Quote. Delayed Euronext Bruxelles - 05/23 11:35:01 am
6.29 EUR   -4.12%
05/15 ABLYNX: Announces q1 2013 business update
05/10ABLYNX NV: quaterly earnings release
05/08 ABLYNX: Publication in accordance with article 14 of the belgian law of 2 ..
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
05/17/2013 05/20/2013 05/21/2013 05/22/2013 05/23/2013 Date
6.55(c) 6.7(c) 6.71(c) 6.56(c) 6.29(c) Last
102 484 89 744 98 428 119 131 212 032 Volume
-1.95% +2.29% +0.15% -2.24% -4.12% Change
More quotes
Company
Ablynx is a biopharmaceutical company specializes in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, thrombosis, oncology and pulmonary... 
Sector
Biotechnology
Calendar
08/21Earnings Release
Surperformance© rating of ABLYNX
Trading Rating : Investor Rating :
More about the company
Chart ABLYNX
Duration : Period :
ABLYNX Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Full-screen chart
Financials (€)
Sales 2013 48,5 M
EBIT 2013 -30,4 M
Net income 2013 -29,8 M
Debt 2013 28,5 M
Yield 2013 -
Sales 2014 36,2 M
EBIT 2014 -30,3 M
Net income 2014 -30,2 M
Debt 2014 12,0 M
Yield 2014 -
PER 2013 -
PER 2014
EV / Sales 2013 7,15x
EV / Sales 2014 9,13x
Capitalization 318 M
More Financials
Latest news on ABLYNX
05/15 ABLYNX: Announces q1 2013 business update
05/10ABLYNX NV: quaterly earnings release
05/08 ABLYNX: Publication in accordance with article 14 of the belgian law of 2 may 2..
05/07 ABLYNX: STARTS PRE-CLINICAL DEVELOPMENT OF ALX-0962, AN ANTI-IgE NANOBODY, TO T..
04/22 ABLYNX: Announces warrant exercise
04/17 ABLYNX: Publication in accordance with article 14 of the belgian law of 2 may 2..
03/26 ABLYNX: Notice of ablynx's annual and extraordinary general meeting of sharehol..
03/08 ABLYNX: Publication in accordance with articles 14 and 15 of the belgian law of..
02/28 ABLYNX (D): Ablynx successfully raises €31.5 million, in total €45 million plac..
02/28 ABLYNX (D): Successfully raises ?31.5 million, in total ?45 million placed
02/27 ABLYNX (D): Ablynx to raise capital via a private placement of new shares
02/27 ABLYNX (D): Announces 2012 full year results
More news
Forum ABLYNX
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Technical analysis
Income Statement Evolution
ABLYNX : Income Statement Evolution
More Financials
EPS Revisions
ABLYNX : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.